416 related articles for article (PubMed ID: 23006423)
1. Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study.
Niu N; Schaid DJ; Abo RP; Kalari K; Fridley BL; Feng Q; Jenkins G; Batzler A; Brisbin AG; Cunningham JM; Li L; Sun Z; Yang P; Wang L
BMC Cancer; 2012 Sep; 12():422. PubMed ID: 23006423
[TBL] [Abstract][Full Text] [Related]
2. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy.
Tan XL; Moyer AM; Fridley BL; Schaid DJ; Niu N; Batzler AJ; Jenkins GD; Abo RP; Li L; Cunningham JM; Sun Z; Yang P; Wang L
Clin Cancer Res; 2011 Sep; 17(17):5801-11. PubMed ID: 21775533
[TBL] [Abstract][Full Text] [Related]
3. Association of GWAS-identified lung cancer susceptibility loci with survival length in patients with small-cell lung cancer treated with platinum-based chemotherapy.
Li D; Wei L; Xu B; Yu D; Chang J; Yuan P; Du Z; Tan W; Shen H; Wu T; Wu C; Lin D
PLoS One; 2014; 9(11):e113574. PubMed ID: 25415319
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
Powrózek T; Mlak R; Krawczyk P; Bartoń S; Biernacka B; Małecka-Massalska T; Milanowski J
Clin Transl Oncol; 2016 Jan; 18(1):33-9. PubMed ID: 26148901
[TBL] [Abstract][Full Text] [Related]
5. RB1 polymorphism contributes to the efficacy of platinum-taxanes in advanced squamous cell lung cancer.
Liu D; Xu W; Zhang ZW; Qian J; Zheng H; Zhang J; Su B
Asian Pac J Cancer Prev; 2015; 16(2):775-81. PubMed ID: 25684524
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer.
Li L; Schaid DJ; Fridley BL; Kalari KR; Jenkins GD; Abo RP; Batzler A; Moon I; Pelleymounter L; Eckloff BW; Wieben ED; Sun Z; Yang P; Wang L
Pharmacogenet Genomics; 2012 Feb; 22(2):105-16. PubMed ID: 22173087
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients.
Vasile E; Tibaldi C; Leon GL; D'Incecco A; Giovannetti E
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1189-94. PubMed ID: 25504507
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Sato Y; Yamamoto N; Kunitoh H; Ohe Y; Minami H; Laird NM; Katori N; Saito Y; Ohnami S; Sakamoto H; Sawada J; Saijo N; Yoshida T; Tamura T
J Thorac Oncol; 2011 Jan; 6(1):132-8. PubMed ID: 21079520
[TBL] [Abstract][Full Text] [Related]
9. Metformin pharmacogenomics: a genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using human lymphoblastoid cell lines.
Niu N; Liu T; Cairns J; Ly RC; Tan X; Deng M; Fridley BL; Kalari KR; Abo RP; Jenkins G; Batzler A; Carlson EE; Barman P; Moran S; Heyn H; Esteller M; Wang L
Hum Mol Genet; 2016 Nov; 25(21):4819-4834. PubMed ID: 28173075
[TBL] [Abstract][Full Text] [Related]
10. Potentially functional genetic variants in the TNF/TNFR signaling pathway genes predict survival of patients with non-small cell lung cancer in the PLCO cancer screening trial.
Guo Y; Feng Y; Liu H; Luo S; Clarke JW; Moorman PG; Su L; Shen S; Christiani DC; Wei Q
Mol Carcinog; 2019 Jul; 58(7):1094-1104. PubMed ID: 30989732
[TBL] [Abstract][Full Text] [Related]
11. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.
Lamba JK; Fridley BL; Ghosh TM; Yu Q; Mehta G; Gupta P
Pharmacogenomics; 2014; 15(12):1565-74. PubMed ID: 25340731
[TBL] [Abstract][Full Text] [Related]
12. A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.
Hong MJ; Lee SY; Choi JE; Jin CC; Kang HJ; Baek SA; Lee SY; Shin KM; Jeong JY; Lee WK; Yoo SS; Lee J; Cha SI; Kim CH; Son JW; Park JY
Oncotarget; 2016 Mar; 7(13):15948-58. PubMed ID: 26893365
[TBL] [Abstract][Full Text] [Related]
13. A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy.
Han JY; Lee YS; Shin ES; Hwang JA; Nam S; Hong SH; Ghang HY; Kim JY; Yoon SJ; Lee JS
Pharmacogenomics J; 2014 Feb; 14(1):20-7. PubMed ID: 23478653
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide analysis of survival in early-stage non-small-cell lung cancer.
Huang YT; Heist RS; Chirieac LR; Lin X; Skaug V; Zienolddiny S; Haugen A; Wu MC; Wang Z; Su L; Asomaning K; Christiani DC
J Clin Oncol; 2009 Jun; 27(16):2660-7. PubMed ID: 19414679
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study.
Lee Y; Yoon KA; Joo J; Lee D; Bae K; Han JY; Lee JS
Carcinogenesis; 2013 Feb; 34(2):307-13. PubMed ID: 23144319
[TBL] [Abstract][Full Text] [Related]
16. Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.
Li Y; Sun Z; Cunningham JM; Aubry MC; Wampfler JA; Croghan GA; Johnson C; Wu D; Aakre JA; Molina J; Wang L; Pankratz VS; Yang P
Clin Cancer Res; 2011 Jun; 17(11):3830-40. PubMed ID: 21636554
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-binding site SNPs in deregulated genes are associated with clinical outcome of non-small cell lung cancer.
Xu J; Tian S; Yin Z; Wu S; Liu L; Qian Y; Pei D; Gao W; Xu J; Yin Y; Liu P; Shu Y
Lung Cancer; 2014 Sep; 85(3):442-8. PubMed ID: 24997136
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness and Resource Usage in Patients Receiving First-line Taxane-based Chemotherapy for Stage IV Non-Small-cell Lung Cancer in a US Community Oncology Setting.
Weiss J; Force RW; Pugmire BA; Peterson T; Faria C; Margunato-Debay S; Patel MB
Clin Lung Cancer; 2017 Jul; 18(4):372-380.e1. PubMed ID: 28117221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
